Novartis AG CAD Hedged CIBC CDR (NVS) Stock Price & Analysis

2 Followers

NVS Stock Chart & Stats

CA$31.71-CA$0.41(-1.28%)

At close: Nov 11 4:00 PM EST

Day’s Range: CAD 31.70 - CAD 31.80
52-Week Range: CAD 23.57 - CAD 33.34
Previous Close: CAD 32.12
Volume: N/A
Average Volume (3M): 580
Market Cap: CAD 421.44B
Enterprise Value: N/A
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): 30.7
Beta: 1.21
Next Earnings: Feb 03, 2027 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Mar 11, 2026
Dividend Yield: 1.78%

Novartis AG CAD Hedged CIBC CDR News

Novartis says long-term Rhapsido data show sustained efficacy

Novartis (NVS) announced 52-week results from the Phase III RemIND program evaluating Rhapsido in chronic inducible urticaria. In the long-term analysis from the RemIND study, Rhapsido 25 mg twice daily

9h agoNVS NOT

Novartis presents long-term results from ongoing NEPTUNUS extension study

Novartis (NVS) presented long-term results from the ongoing NEPTUNUS extension study of ianalumab in Sjogren’s disease at the American College of Rheumatology Convergence 2026. The data showed that the reduction

2d agoNVS NOT

FDA warns of NAION vision loss risk with GLP-1 RA drugs

The Food and Drug Administration is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy associated with use of glucagon-like peptide-1 receptor

3d agoLLY NVS

Weekend Fly By: Top five stock stories

Catch up on the weekend’s top five stories with this list compiled by The Fly: Nvidia (NVDA) said in a statement that its board is “initiating an independent investigation in

4d agoANT NVS

Novartis to discontinue development of pelacarsen, Bloomberg says

Novartis (NVS) is discontinuing the development of pelacarsen, a drug that was meant to treat atherosclerotic cardiovascular disease, Fabienne Kinzelmann and Robert Langreth of Bloomberg reports. The move comes after

4d agoNVS NOT

Novartis price target raised to CHF 150 from CHF 135 at Citi

Citi raised the firm’s price target on Novartis (NVS) to CHF 150 from CHF 135 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate

6d agoNVS NOT

BioArctic says Novartis terminates collaboration agreement

BioArctic AB (BRCTF) announced that Novartis (NVS) has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a

1w agoNVS NOT

Novartis downgraded to Sell at Deutsche Bank on pending exclusivity cliff

As previously reported, Deutsche Bank analyst Emmanuel Papadakis downgraded Novartis (NVS) to Sell from Hold with a price target of CHF 115, down from CHF 120, after what the firm

1w agoNVS NOT

Novartis downgraded to Sell from Hold at Deutsche Bank

Deutsche Bank downgraded Novartis (NVS) to Sell from Hold with a price target of CHF 115, down from CHF 120. Published first on TheFly – the ultimate source for real-time,

1w agoNVS NOT

Novartis price target raised to CHF 145 from CHF 135 at JPMorgan

JPMorgan raised the firm’s price target on Novartis (NVS) to CHF 145 from CHF 135 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate

2w agoNVS NOT

Novartis Upgraded to ‘Safe Haven’ Buy as Analyst Lifts Price Target to SFr 135 on Margin Upside and Mid-Term Growth

Morgan Stanley analyst Thibault Boutherin maintained a Buy rating on Novartis AG today and set a price target of CHF135.00. Thibault Boutherin has given his Buy rating due to a

2w agoNVS NOT

Novartis: Buy Rating Reaffirmed on Earnings Beat, Improved Profitability and Underappreciated Growth; Price Target Unchanged at $150

Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on Novartis AG and keeping the price target at CHF150.00. Sachin Jain has given his Buy rating due

2w agoNVS NOT

Buy Rating Reiterated on Robust Growth Outlook and Pipeline Strength; Price Target Maintained at 150 CHF

Analyst Sachin Jain of Bank of America Securities maintained a Buy rating on Novartis AG, retaining the price target of CHF150.00. Sachin Jain has given his Buy rating due to

2w agoNVS NOT

Novartis: Pipeline and Key Assets Seen Offsetting $20B Patent Headwind; Buy Rating Reiterated with Unchanged $150 Price Target

Sachin Jain, an analyst from Bank of America Securities, maintained the Buy rating on Novartis AG. The associated price target remains the same with CHF150.00. Sachin Jain has given his

1M agoNVS NOT

NVS FAQ

What was Novartis AG CAD Hedged CIBC CDR’s price range in the past 12 months?

Novartis AG CAD Hedged CIBC CDR lowest stock price was C$23.57 and its highest was C$33.34 in the past 12 months.

What is Novartis AG CAD Hedged CIBC CDR’s market cap?

Novartis AG CAD Hedged CIBC CDR’s market cap is C$421.44B.

When is Novartis AG CAD Hedged CIBC CDR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Novartis AG CAD Hedged CIBC CDR overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Novartis AG CAD Hedged CIBC CDR pay dividends?

Novartis AG CAD Hedged CIBC CDR pays a dividend of C$0.566 which represents an annual dividend yield of 1.78%. See more information on Novartis AG CAD Hedged CIBC CDR dividends here

What is Novartis AG CAD Hedged CIBC CDR’s EPS estimate?

Novartis AG CAD Hedged CIBC CDR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Novartis AG CAD Hedged CIBC CDR have?

Novartis AG CAD Hedged CIBC CDR has 2,034,819,500 shares outstanding.

Which hedge fund is a major shareholder of Novartis AG CAD Hedged CIBC CDR?

Currently, no hedge funds are holding shares in TSE:NVS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Novartis AG CAD Hedged CIBC CDR

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG CAD Hedged CIBC CDR (NVS) Earnings & Revenues

Historic Earnings Reports

NVS Earnings Call

Q3 2026

Earnings Call SentimentPositive

The call was strongly positive overall. Q3 delivered sales growth, significant core operating income and margin expansion, strong momentum across priority brands, multiple pipeline milestones and an upgrade to full-year core operating income guidance. These positives outweighed substantial negatives, including the delgociptacine impairment, failed pelacarsen primary endpoint, lower reported net income, prior Entresto generic erosion, expected Xolair biosimilar pressure and several unresolved regulatory or clinical-development issues.

View all TSE:NVS earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	13	5	4
Technical Analysis	4	5	1
Moving Averages	9	0	3

Technical Analysis >

Similar Stocks

Stocks similar to TSE:NVS
Company	Price & Change	Follow
TSE:BHCBausch Health Companies
TSE:ROGRoche Holding Ltd CAD Hedged CIBC CDR

Compare TSE:NVS Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

NVS Stock Chart & Stats

Novartis AG CAD Hedged CIBC CDR News

Novartis says long-term Rhapsido data show sustained efficacy

Novartis presents long-term results from ongoing NEPTUNUS extension study

FDA warns of NAION vision loss risk with GLP-1 RA drugs

Weekend Fly By: Top five stock stories

Novartis to discontinue development of pelacarsen, Bloomberg says

Novartis price target raised to CHF 150 from CHF 135 at Citi

BioArctic says Novartis terminates collaboration agreement

Novartis downgraded to Sell at Deutsche Bank on pending exclusivity cliff

Novartis downgraded to Sell from Hold at Deutsche Bank

Novartis price target raised to CHF 145 from CHF 135 at JPMorgan

Novartis Upgraded to ‘Safe Haven’ Buy as Analyst Lifts Price Target to SFr 135 on Margin Upside and Mid-Term Growth

Novartis: Buy Rating Reaffirmed on Earnings Beat, Improved Profitability and Underappreciated Growth; Price Target Unchanged at $150

Buy Rating Reiterated on Robust Growth Outlook and Pipeline Strength; Price Target Maintained at 150 CHF

Novartis: Pipeline and Key Assets Seen Offsetting $20B Patent Headwind; Buy Rating Reiterated with Unchanged $150 Price Target

NVS FAQ

Company Description

Novartis AG CAD Hedged CIBC CDR

Novartis AG CAD Hedged CIBC CDR (NVS) Earnings & Revenues

NVS Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive